Deflux safety established over two decades of use
Since 1998, Deflux has been used for more to treat vesicoureteral reflux (VUR) in children. Deflux is made from two naturally occurring biocompatible materials: Non-Animal Hyaluronic Acid (NASHA®) and Dextranomer microspheres (Dx). The hyaluronic acid in Deflux, NASHA, has been used in more than 40 million procedures worldwide.1
Deflux is the only injectable agent for VUR approved in Australia, Canada, Europe, New Zealand and the United States.
The following adverse events have been reported with Deflux (occurring ≤ 1%): postoperative dilation of the upper urinary tract that resolves spontaneously within a few days, postoperative dilation of the upper urinary tract with or without hydronephrosis leading to temporary placement of a ureteric stent. In very rare cases of ureteral obstruction, ureteric reimplantation has been required.2
The components used for the manufacturing of Deflux injectable gel are free from Latex.
Please see the product insert for full safety information.